United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, HC Wainwright Analyst Says

United Therapeutics (NASDAQ:UTHR) had its price target boosted by HC Wainwright from $525.00 to $600.00 in a research note issued to investors on Thursday, MarketBeat reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 19.07% from the stock’s current price.

A number of other equities analysts also recently commented on UTHR. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a research note on Wednesday. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Wells Fargo & Company upped their target price on United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research report on Thursday. TD Cowen upped their price target on United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Morgan Stanley set a $447.00 price objective on United Therapeutics in a research report on Wednesday, October 29th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $533.55.

United Therapeutics Stock Up 0.1%

United Therapeutics stock opened at $503.90 on Thursday. The firm has a fifty day moving average of $484.38 and a 200-day moving average of $445.92. The firm has a market capitalization of $22.09 billion, a P/E ratio of 18.06, a PEG ratio of 1.79 and a beta of 0.85. United Therapeutics has a 52-week low of $266.98 and a 52-week high of $537.19.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. During the same quarter last year, the firm earned $6.19 earnings per share. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. On average, research analysts expect that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $479.91, for a total transaction of $10,797,975.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO James Edgemond sold 21,000 shares of United Therapeutics stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $479.99, for a total value of $10,079,790.00. Following the completion of the transaction, the chief financial officer owned 8,142 shares in the company, valued at $3,908,078.58. The trade was a 72.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 407,954 shares of company stock worth $197,601,528 over the last three months. Company insiders own 10.30% of the company’s stock.

Institutional Trading of United Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Clearstead Advisors LLC grew its position in United Therapeutics by 8.9% during the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after buying an additional 23 shares in the last quarter. Independent Advisor Alliance raised its stake in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after acquiring an additional 27 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company’s stock worth $472,000 after purchasing an additional 28 shares during the last quarter. Florida Financial Advisors LLC raised its stake in shares of United Therapeutics by 5.4% in the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company’s stock worth $268,000 after acquiring an additional 28 shares during the last quarter. Finally, NDVR Inc. increased its stake in shares of United Therapeutics by 5.1% in the 4th quarter. NDVR Inc. now owns 616 shares of the biotechnology company’s stock valued at $300,000 after buying an additional 30 shares during the period. 94.08% of the stock is owned by institutional investors.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 outperformance and growth target — UTHR beat EPS expectations (reported strength in Tyvaso DPI sales) and management is targeting roughly a $4B revenue run‑rate by 2027 as several late‑stage product launches approach; this underpins the recent rally and longer‑term growth thesis. Read More.
• Positive Sentiment: Analysts lifting targets — Multiple firms raised price targets (examples: H.C. Wainwright, RBC, Oppenheimer), which supports further upside and institutional interest. Read More.
• Positive Sentiment: Bullish options flow — Unusually large call buying around the print suggests traders are positioning for further upside or volatility in the short term. Read More.
• Neutral Sentiment: Technical/relative strength recognition — UTHR earned a high RS rating (91), signaling market leadership but not guaranteeing direction near term. Read More.
• Neutral Sentiment: Mixed analyst views remain — while many bumped targets, some firms kept Hold/equal‑weight ratings, leaving near‑term consensus mixed. Read More.
• Negative Sentiment: Revenue missed consensus — Q4 revenue came in below Street estimates, which sparked an earlier pullback and is a reminder top‑line execution matters for the multiple. Read More.
• Negative Sentiment: Insider selling — The COO and a director disclosed multi‑lot sales in February (COO sale worth several million and director sales disclosed), which can create investor concern about near‑term insider conviction. Read More. Read More.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.